Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
作者信息
Jain Preetesh, Kanagal-Shamanna Rashmi, San Lucas F Anthony, Nastoupil Loretta, Romaguera Jorge, Fayad Luis, Oki Yasuhiro, Westin Jason R, Medeiros Leonard Jeffrey, Wang Michael, Fowler Nathan
机构信息
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Br J Haematol. 2018 Sep;182(5):718-723. doi: 10.1111/bjh.14857. Epub 2017 Aug 2.
Abstract
摘要
相似文献
1
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Br J Haematol. 2018 Sep;182(5):718-723. doi: 10.1111/bjh.14857. Epub 2017 Aug 2.
2
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Hematol Oncol Clin North Am. 2020 Oct;34(5):903-921. doi: 10.1016/j.hoc.2020.06.007. Epub 2020 Aug 1.
3
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Haematologica. 2019 Nov;104(11):2292-2299. doi: 10.3324/haematol.2018.207183. Epub 2019 Feb 28.
4
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Blood. 2018 Jan 11;131(2):182-190. doi: 10.1182/blood-2017-09-804641. Epub 2017 Oct 26.
5
Second-generation inhibitors of Bruton tyrosine kinase.
J Hematol Oncol. 2016 Sep 2;9(1):80. doi: 10.1186/s13045-016-0313-y.
6
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Hematol Oncol Clin North Am. 2018 Oct;32(5):853-864. doi: 10.1016/j.hoc.2018.05.012. Epub 2018 Jul 19.
7
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
Clin Adv Hematol Oncol. 2021 Jul;19(7):436-438.
8
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Leukemia. 2017 Oct;31(10):2075-2084. doi: 10.1038/leu.2017.32. Epub 2017 Jan 23.
9
Resistance mechanism for ibrutinib in marginal zone lymphoma.
Blood Adv. 2019 Feb 26;3(4):500-502. doi: 10.1182/bloodadvances.2018029058.
10
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
J Pharmacol Exp Ther. 2020 Mar;372(3):331-338. doi: 10.1124/jpet.119.262063. Epub 2019 Dec 23.
引用本文的文献
1
Unraveling the complexity of follicular lymphoma: insights and innovations.
Am J Cancer Res. 2024 Dec 15;14(12):5573-5597. doi: 10.62347/MFUG2190. eCollection 2024.
2
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
Blood Adv. 2021 Nov 23;5(22):4674-4685. doi: 10.1182/bloodadvances.2021004528.
本文引用的文献
1
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
Blood. 2017 Jan 26;129(4):473-483. doi: 10.1182/blood-2016-07-729954. Epub 2016 Nov 14.
2
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.
3
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Nat Commun. 2016 May 20;7:11589. doi: 10.1038/ncomms11589.
4
Postibrutinib outcomes in patients with mantle cell lymphoma.
Blood. 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13.
5
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.
6
Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.
Blood Cancer J. 2015 Oct 16;5(10):e361. doi: 10.1038/bcj.2015.89.
7
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Blood. 2015 Mar 26;125(13):2062-7. doi: 10.1182/blood-2014-09-603670. Epub 2015 Jan 8.
8
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.
Blood. 2015 Jan 22;125(4):658-67. doi: 10.1182/blood-2014-04-571786. Epub 2014 Dec 1.
9
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Cancer Discov. 2014 Sep;4(9):1022-35. doi: 10.1158/2159-8290.CD-14-0098. Epub 2014 Jul 31.
Zotero 插件